The collaboration will focus on the development and commercialisation of multiple monoclonal antibody products targeting oncology and inflammatory diseases.
Under the agreement, BRL will undertake proof-of-concept and formulation development activities, while Ipca will be responsible for further research and development, clinical trials, commercial manufacturing and product launches.
The licensing arrangement covers worldwide rights. BRL will receive a defined milestone fee related to the technology transfer and will also earn royalties on net sales upon commercialisation of the products.
Commenting on the partnership, Pranay Godha, Managing Director and Chief Executive Officer of Ipca Laboratories, said the collaboration combines Ipca’s scientific capabilities with BRL’s formulation platform to accelerate the development of affordable biologics for patients battling cancer and autoimmune diseases globally.
BRL Co-founder and Chief Executive Officer Dr Suryakanth M Pai said the partnership would expand the reach of the company’s proprietary and patented subcutaneous protein delivery platform technology and help develop differentiated biologics for global markets. He added that the collaboration is aimed at making patient care more convenient, affordable and safe.
Akhil Shah, Director and Chief Executive Officer of WeTranslate, said BRL has built a differentiated formulation technology platform, while Ipca brings the scale, expertise and global reach required for commercialisation. He added that WeTranslate was pleased to support the collaboration and its potential impact on biologic drug delivery.
Q4FY26 results
Ipca Laboratories had reported a steady set of fourth-quarter earnings with growth in domestic formulations and exports helping improve revenue and operating margins during the March quarter.
Profit before exceptional items and tax rose to ₹450 crore in Q4FY26 from ₹333 crore a year ago. Revenue for the quarter increased 6.3% year-on-year to ₹2,388.5 crore, while EBITDA rose 12.7% to ₹484 crore.
Shares of Ipca Laboratories Ltd ended Friday’s session at ₹1,589 apiece on the NSE, down 1.52% or ₹24.60 from the previous close.
Also Read: A ₹750 crore fund looking to invest in DeepTech startups
